Recombinant pituitary growth hormones, also known as recombinant human growth hormones (rhGH), are synthetic forms of the naturally occurring growth hormone produced by the pituitary gland. These hormones are produced through a process known as recombinant DNA technology, which involves inserting the gene that codes for human growth hormone into a host organism, such as bacteria or yeast, to produce large quantities of the hormone.
These recombinant pituitary growth hormones are used clinically to treat individuals with growth hormone deficiency, a condition characterized by inadequate production of growth hormone by the pituitary gland. They are also used for various medical conditions in which growth hormone therapy is warranted, such as Turner syndrome, chronic kidney disease, and Prader-Willi syndrome.
The primary function of recombinant pituitary growth hormones is to promote growth and development in individuals with growth hormone deficiency. They stimulate the growth of long bones, increase muscle mass, and promote the synthesis of proteins in the body. In addition to their role in promoting physical growth, these hormones also have metabolic effects which include promoting fat utilization, regulating blood sugar levels, and enhancing bone mineralization.
Recombinant pituitary growth hormones are administered through subcutaneous injections and require careful monitoring by healthcare professionals to adjust the dosage as needed. While generally safe and well-tolerated, there are potential side effects associated with their use, such as fluid retention, joint pain, and increased risk of diabetes. Therefore, close medical supervision is necessary for individuals receiving recombinant pituitary growth hormone therapy.
